Evidence map›Paper›PMID 25688547›Full record

ArticleYeast (Chichester, England)2015

Puromycin- and methotrexate-resistance cassettes and optimized Cre-recombinase expression plasmids for use in yeast.

Chris MacDonald, Robert C Piper

Open access · greenAbstract read
In one paragraph

Article in Yeast (Chichester, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A probiotic yeast-based immunotherapy againstScience translational medicine · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chris MacDonaldDepartment of Molecular Physiology and Biophysics, University of Iowa, IA, USA.
Robert C Piper
University of Iowa · US

Funding

Ubiquitin-Dependent Sorting in Endosomes and the TGNR01GM058202 · NIGMS · UNIVERSITY OF IOWA · PI PIPER, ROBERT C · 1998 to 2025
$8.9M
Quantitative mapping of ubiquitin ligase substratesR01GM094830 · NIGMS · UNIVERSITY OF IOWA · PI PIPER, ROBERT C, WRIGHT, MICHAEL E · 2010 to 2013
$1.2M
NIGMS NIH HHS R01 GM058202NIGMS NIH HHS R01 GM094830
6 · The paper itself

Abstract

Here we expand the set of tools for genetically manipulating Saccharomyces cerevisiae. We show that puromycin-resistance can be achieved in yeast through expression of a bacterial puromycin-resistance gene optimized to the yeast codon bias, which in turn serves as an easy-to-use dominant genetic marker suitable for gene disruption. We have constructed a similar DNA cassette expressing yeast codon-optimized mutant human dihydrofolate reductase (DHFR), which confers resistance to methotrexate and can also be used as a dominant selectable marker. Both of these drug-resistant marker cassettes are flanked by loxP sites, allowing for their excision from the genome following expression of Cre-recombinase. Finally, we have created a series of plasmids for low-level constitutive expression of Cre-recombinase in yeast that allows for efficient excision of loxP-flanked markers.

Indexed as

Drug Resistance, FungalCodonGenetic MarkersIntegrasesMethotrexatePlasmidsProtein EngineeringPuromycinSaccharomyces cerevisiaeCodonCre recombinaseGenetic MarkersIntegrasesMethotrexatePuromycin

Identifiers

PMID25688547
PMCPMC4454448
OpenAlexW1961189042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.